Drugs / CC-90006
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03337022 | Jan 2018 → Apr 2019 | psoriasis | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02934269 | Nov 2016 → Aug 2017 | — | Celgene Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-90006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02934269 ↗ |
| Known as | Cc-90006 pd-1 agonist | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594467 ↗ |
| Route | Subcutaneous | “CC-90006 will be administered by subcutaneous injection in the abdomen” NCT02934269 ↗ |